Figure 1 B-Scan image of TD-OCT with wet AMD Scorcia and Rechichi BMC Geriatrics 2010, 10(Suppl 1):A78
Background Age-related macular degeneration (AMD) is the leading cause of severe vision loss in the developed world in patients over 60 years. AMD is characterized by two distinct forms: dry and wet. Optical coherence tomography (OCT) is a non-invasive, useful and reproducible diagnostic tool that provides cross-sectional images of retina and has a primary role for diagnostic and therapeutic management of AMD. The spread of anti-VEGF intravitreal injection for therapy of wet AMD further emphasized the role of OCT for treatment algorithms allowing a precise characterization of lesions and strict non-invasive retinal monitoring in the follow-up.
Main indications and limits of OCT will be discussed as well as the various morphological presentations of dry and wet AMD underlying retinal changes before and after therapy.
Materials and methods
We analyzed 500 eyes of 270 patients affected by dry or wet AMD that underwent a complete ophthalmological examination and OCT scan with two different machines. A time domain OCT (TD-OCT, Stratus OCT3, Carl Zeiss Meditec, Dublin, CA) and a Fourier Domain OCT (FD-OCT, RTVue-100, Optovue, Fremont, CA).
We used a radial line pattern scan algorithm with TD-OCT (see Figure 1 ) and radial and raster scan with FD-OCT with additional tridimensional reconstruction (see Figure 2 ).
Results
B-scan analysis of two instruments allows detailed reproduction of anatomical retinal layers in AMD. FD-OCT images are more accurate and the computing process allows tridimesional reconstruction of sagittal and coronal plane.
Conclusions
Optical coherence tomography is a simply, non-invasive and reproducible technique for retinal imaging in patients with AMD. The spread of FD-OCT allows a precise characterization of AMD and accurate analysis of intraretinal layers. Tridimentional reconstruction tomography improves the visualization of photoreceptor morphology. Scorcia and Rechichi BMC Geriatrics 2010, 10(Suppl 1):A78 http://www.biomedcentral.com/1471-2318/10/S1/A78
